SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Stellar is an open-source, decentralized network co-founded in 2014 by Jed McCaleb and Joyce Kim to facilitate the fast and low-cost transfer of value across different currencies and assets globally. Managed by the non-profit Stellar Development Foundation, the project serves as a global infrastructure that connects banks, payment systems, and individuals to expand financial access to underserved populations. Its main value proposition lies in providing a bridge between traditional money and digital networks through the use of Anchors, which are trusted entities that hold deposits and issue credits on the ledger.  The network operates using the Stellar Consensus Protocol and a Federated Byzantine Agreement, where nodes choose trusted sets of other nodes to agree on the state of the ledger. This system ensures high throughput and fast finality, where transactions are considered permanent and irreversible within seconds. Key features include a built-in distributed exchange for trading assets without intermediaries and the Soroban platform for developing smart contracts. Users can also utilize the network for tokenizing real-world assets or accessing decentralized finance services like peer-to-peer lending.  Stellar's native token, XLM, is essential for maintaining network integrity by acting as an intermediary to find efficient exchange paths and preventing spam through small transaction fees and minimum account balance requirements. Unlike many other digital assets, the network has no inflation because the community voted to disable the automatic creation of new tokens. While the project received early funding from the payments company Stripe, it is now sustained by a global community of validators and developers rather than traditional venture capital.

Stellar Lumens

Stellar Lumens is trending due to a high-profile integration with the Depository Trust & Clearing Corporation (DTCC), which plans to bring tokenized securities onto the Stellar network by 2027. The community is actively debating the project's long-term utility against market volatility, with many users focused on its potential for institutional adoption while others speculate on price targets and the potential for a long-term squeeze.

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

Hedera Hashgraph is facing intense community debate as investors weigh its enterprise utility and Governing Council partnerships against persistent price stagnation and concerns over token dilution. While some holders remain committed to the long-term potential of its institutional-grade infrastructure, others are expressing frustration over the lack of sustained price momentum compared to broader market trends.

Filtronic Plc engages in the provision of radio frequency technology. Its products include Morpheus II, Cerus, tower top amplifiers, Orpheus, GaN amplifiers, custom filters, switched filter banks, transceivers, transmit and receive modules, and others. It operates through the following geographical segments: United Kingdom, Europe, Americas, and Rest of the World. The company was founded by John David Rhodes in 1977 and is headquartered in Sedgefield, the United Kingdom.

Filtronic

Filtronic Plc

Filtronic is gaining significant community traction as a strategic, picks-and-shovels supplier to the Starlink ecosystem, with investors highlighting its critical role in RF/mmWave infrastructure and its ongoing contract expansion with SpaceX. Discussion remains heavily focused on the company's potential as a long-term play on satellite sector growth, with many investors closely monitoring its technological importance and the potential for a valuation re-rate as Starlink scales.

Sui s a Layer 1 blockchain developed by Mysten Labs, a team founded by former lead engineers from Meta’s blockchain research division. It is designed for global adoption by providing a secure, high-speed environment for digital asset ownership and removing technical barriers for Web3 applications. The platform utilizes the Move programming language to create a safe framework and supports horizontal scaling to keep fees stable and speeds high as the network grows. Significant institutional support comes from major venture capital firms including Andreessen Horowitz, Coinbase Ventures, Circle Ventures, and YZi Labs.  The system functions by organizing data into independent objects rather than a single ledger of accounts. This object-centric data model enables parallel execution, allowing the network to process many transactions simultaneously instead of waiting for one to finish before starting the next. This architecture is built for rapid transaction finalization to ensure near-instant results. To maintain long-term stability, the network collects fees into a storage fund that rewards validators for keeping data on the network indefinitely.  Sui offers several advanced tools including zkLogin for easier account access and sponsored transactions that allow users to interact with apps without managing complex wallets or immediate fees. Developers can also create tailored object types that work across the entire network, which encourages innovation and deep composability. These features are designed to create a more user-friendly experience for interacting with decentralized applications and digital games.  The SUI token is central to the ecosystem, serving as the primary asset for transaction fees and on-chain utility within decentralized exchanges and lending platforms. Users participate in a proof-of-stake mechanism by locking their tokens to support validators and secure the blockchain in exchange for rewards. Additionally, token holders have a role in governance, allowing them to participate in voting on network rules and future protocol upgrades. Value moves through the system through these staking rewards and transaction fees to ensure the platform scales sustainably

SUI is trending following back-to-back major network outages that have halted transaction processing and sparked intense debate over the platform's long-term reliability and technical stability. While some members of the community are expressing frustration and liquidating their positions, others are framing the price dip as a strategic buying opportunity, betting on the network's underlying technology and future integrations.

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Definium Therapeutics Inc.

Definium Therapeutics is drawing significant investor interest as it approaches a series of major Phase 3 topline data readouts for its MDD and GAD programs, with the community closely tracking the potential for regulatory fast-tracking. While bulls are focused on the catalyst-heavy pipeline and substantial cash runway, debates remain heated over historical management performance and the dilution risks associated with continued clinical development.

NEOS ETF Trust - NEOS S&P 500 High Income ETF

NEOS S&P 500 High Income ETF

The NEOS S&P 500 High Income ETF (SPYI) is trending as income-focused investors actively discuss its monthly distribution strategy, tax efficiency via Section 1256 contracts, and its role as a core holding alongside QQQI and JEPQ. Community sentiment is driven by the ETF's ability to maintain exposure to the S&P 500 while generating consistent cash flow, with many highlighting its reliability during sideways market conditions as a key differentiator.

C3.ai, Inc. engages in the provision of enterprise artificial intelligence software for digital transformation. It delivers the C3 AI suite for developing, deploying, and operating large-scale AI, predictive analytics, and Internet of Things applications in addition to a portfolio of turn-key AI applications. It operates through the following geographical segments: North America, Europe, The Middle East, and Africa, Asia Pacific, and Rest of World. The company was founded by Thomas M. Siebel, Patricia A. House and Stephen Maurice Ward, Jr. on January 8, 2009 and is headquartered in Redwood City, CA.

C3.ai Inc - Ordinary Shares - Class A

C3.ai Inc

C3.ai is experiencing heightened volatility and trading volume as community members debate the impact of potential government contract wins and speculative merger rumors. Investors are closely monitoring the stock's significant short interest, with many hoping for a squeeze to drive shares toward double digits amid broader sector interest in industrial AI applications.

NEOS ETF Trust - NEOS Nasdaq 100 High Income ETF

NEOS Nasdaq 100 High Income ETF

QQQI is capturing significant attention as investors leverage its covered call overlay to secure consistent, high-yield monthly income while maintaining Nasdaq-100 exposure. The community is actively discussing its tax efficiency and utility as a "cash machine" for long-term retirement planning, with many prioritizing systematic reinvestment of distributions to compound wealth across various market conditions.

Kazia Therapeutics Ltd. is an oncology-focused biotechnology company, which engages in the business of pharmaceutical drug development. It focuses on its Paxalisib program, which is designed to treat brain cancer. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia.

Kazia Therapeutics Limited - ADR

Kazia Therapeutics

Kazia Therapeutics is trending following the disclosure of encouraging preliminary clinical data for its lead oncology asset, paxalisib, which showed potential for inducing tumor regression in advanced triple-negative breast cancer cases. The community is actively discussing the stock's significant upside potential relative to its current valuation, the ongoing intellectual property protection strategy involving withdrawn clinical abstracts, and the high-conviction buying activity by major stakeholders.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Replimune Group Inc. is trending as investors digest news of a potential path forward for the resubmission of its melanoma treatment, RP1, following productive discussions with the FDA. While some in the community view this as a potential third-try turnaround for the stock, others remain cautious, pointing to historical regulatory hurdles, the company's limited capital runway, and the ongoing debate over the drug's trial design.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Pro-Dex (NASDAQ:PDEX) Releases Earnings Results, Beats Estimates By $0.58 EPS

Pro-Dex (NASDAQ:PDEX - Get Free Report) posted its quarterly earnings data on Thursday. The medical instruments supplier reported $1.20 earnings per share (EPS) for the quarter, topping analysts...

Pro-Dex (NASDAQ:PDEX) Share Price Passes Above 200 Day Moving Average   - Should You Sell?

Pro-Dex (NASDAQ:PDEX) Share Price Passes Above Two Hundred Day Moving Average - Should You Sell...

Pro-Dex (PDEX) Projected to Post Quarterly Earnings on Wednesday

Pro-Dex (NASDAQ:PDEX) will be releasing its Q3 2026 earnings before the market opens on Wednesday, April 29. (View Earnings Report at...

Pro-Dex (NASDAQ:PDEX) Stock Price Passes Above 200 Day Moving Average   - Should You Sell?

Pro-Dex (NASDAQ:PDEX) Shares Cross Above Two Hundred Day Moving Average - What's Next...

Pro-Dex (NASDAQ:PDEX) Share Price Crosses Above Two Hundred Day Moving Average - Here's What Happened

Pro-Dex (NASDAQ:PDEX) Stock Passes Above 200-Day Moving Average - Time to Sell...

Pro-Dex (NASDAQ:PDEX) Stock Price Crosses Above 200 Day Moving Average - Here's Why

Pro-Dex (NASDAQ:PDEX) Shares Cross Above 200-Day Moving Average - Here's Why...

Pro-Dex (NASDAQ:PDEX) Stock Price Passes Above 200 Day Moving Average - Here's Why

Pro-Dex (NASDAQ:PDEX) Share Price Crosses Above 200 Day Moving Average - Time to Sell?

Pro-Dex (NASDAQ:PDEX) Shares Cross Above 200-Day Moving Average - What's Next...

Pro-Dex (NASDAQ:PDEX) Stock Crosses Above 200 Day Moving Average - Should You Sell?

Pro-Dex (NASDAQ:PDEX) Share Price Crosses Above Two Hundred Day Moving Average - Time to Sell...

Pro-Dex (NASDAQ:PDEX) Stock Crosses Above 200-Day Moving Average - What's Next?

Pro-Dex (NASDAQ:PDEX) Shares Cross Above 200 Day Moving Average - Time to Sell...

Pro-Dex, Inc. engages in the design, development and manufacture of rotary drive surgical and dental instruments. The firm specializes in medical devices and services, industrial and scientific, dental and component, repairs and other. Its products include finished medical devices, micro air-motors, dental products, plastic injection molding and torque wrenches. The company was founded on January 26, 1994 and is headquartered in Irvine, CA.

PDEX
Pro-Dex Inc. (co)

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Latest PDEX News

PDEXPro-Dex Inc. (co)